Preparation of a disulfide-linked precipitative soluble support for solution-phase synthesis of trimeric oligodeoxyribonucleotide 3´-(2-chlorophenylphosphate) building blocks

Amit M. Jabgunde*1,2, Alejandro Gimenez Molina1, Pasi Virta1 and Harri Lönnberg1

Abstract
The preparation of a disulfide-tethered precipitative soluble support and its use for solution-phase synthesis of trimeric oligodeoxyribonucleotide 3´-(2-chlorophenylphosphate) building blocks is described. To obtain the building blocks, N-acyl protected 2´-deoxy-5´-O-(4,4´-dimethoxytrityl)ribonucleosides were phosphorylated with bis(benzotriazol-1-yl) 2-chlorophenyl phosphate. The “outdated” phosphotriester strategy, based on coupling of P5 building blocks in conjunction with quantitative precipitation of the oligodeoxyribonucleotide with MeOH is applied. Subsequent release of the resulting phosphate and base-protected oligodeoxyribonucleotide trimer 3´-pTpdC-BzpdG-bio-5´ as its 3´-(2-chlorophenyl phosphate) was achieved by reductive cleavage of the disulfide bond.

Introduction
Synthetic nucleic acids have been used to regulate gene expression through different mechanisms of action, such as antisense oligonucleotides [1,2], ribozymes [3], interfering RNAs (siRNA) [4,5] and immunostimulatory CpG [6] based therapeutics. At the same time, the interest in detailed understanding of the factors that govern the interaction of nucleic acids with small molecular entities and other biopolymers has increased. In particular, for NMR spectroscopic studies of such interactions, oligonucleotides are often required in quantities that are inconvenient to prepare by laboratory scale solid-phase synthesis. We have previously reported that short oligonucleotides may be conveniently prepared in hundreds of milligrams scale on a soluble tetrakis-O-[4-(1,2,3-triazol-1-yl)methyl]pentacyclic thitol support that precipitates quantitatively from MeOH [7-10]. For example, the “outdated” phosphotriester strategy [11-14], exploiting 3´-(2-chlorophenyl phosphate) building blocks works well on this support [8]. No oxidation step is needed and the coupling cycle, hence, contains only two steps: 5´-deprotection and coupling. To prepare long sequences, it may, however, be necessary to apply convergent solution-phase
coupling of oligomeric 3’-(2-chlorophenyl phosphate) building blocks [15]. For the preparation of such building blocks, a 2-hydroxyethyl-disulfanyl functionalized support may in principle be used [16-21]. After completion of the chain assembly on the hydroxy function, the disulfide linkage may be reductively cleaved and the phosphate bound 2- mercaptoethyl group is removed. Accordingly, the oligomer expectedly is released in a fully protected form. We now report on the synthesis of such a soluble support, 3, and show that it allows efficient coupling by the 1-hydroxybenzotriazole promoted phosphotriester coupling [11,22,23] and efficient purification of the support bound product by precipitation from MeOH after each deprotection and coupling step.

Results and Discussion

The synthesis of the disulfide tethered tetrakis-O-4-[2-hydroxyethyl-disulfanyl]methyl]-1H-1,2,3-triazol-1-ylmethyl]pentaerythritol support (3) is outlined in Scheme 1. Commercially available S-propargyl thioacetate was first conjugated to the tetrakis-O-[4-(azidomethylphenyl)pentaerythritol support (1) [7] by Cu(I) catalyzed 1,3-dipolar cycloaddition [24,25], yielding tetrakis- O-4-[4-(acetylthio- methyl)]-1H-1,2,3-triazol-1-ylmethyl]phenyl]pentaerythritol (2) as a thick oil. Careful aminolysis of the thioacetates with butylamine in degassed methanol under inert atmosphere followed by immediate reaction of the exposed mercapto groups with 2-(pyridine-2-yl-disulfanyl)ethanol gave the desired tetrapodal soluble support 3.

Previously [11] described phosphorylation with bis(benzotriazol-1-yl) 2-chlorophenyl phosphate in 1,4-dioxane was applied to convert commercial thymidine, N4-benzoyl-2’-deoxycytidine and N2-isobutyl-2’-deoxyguanosine into their 3’-(benzotriazol-1-yl 2-chlorophenyl phosphates) (4–6; Scheme 2). The stock solution of the latter reagent (0.2 mol L−1) was prepared as described in our previous report [8].

A trimeric oligodeoxyribonucleotide containing three different 2’-deoxyribonucleosides was assembled on support 3 as depicted in Scheme 3. The couplings were carried out essentially as described previously [8]. Accordingly, the dried support was treated under nitrogen with the thymidine derived building block 4 (2 equiv per support-bound OH), in dioxane in the presence of 1-methylimidazole. The coupling was

---

**Scheme 1:** Synthesis of soluble support. Reagents and conditions: (i) CuI, sodium ascorbate, DMAC, 50 °C, 12 h; (ii) butylamine, MeOH, room temperature, 12 h; (iii) 2-(pyridine-2-yl-disulfanyl)ethanol, MeCN/DCM/MeOH, 0.5 h.

**Scheme 2:** Activation of nucleosides. Reagents and conditions: (i) pyridine, dry dioxane, room temperature, 3 h.

1554
completed in 12 h, and the excess of 4 and the coupling reagents were removed by precipitating the support with MeOH to obtain 7a. According to TLC analysis, the precipitation was quantitative. Detritylation of 7a with HCl in a 1:1 mixture of MeOH and DCM, followed by neutralization with pyridine, concentration to oil and precipitation from MeOH, afforded 7b. HPLC-analysis verified the completeness of precipitation (Figure 1).

Building blocks 5 and 6 were then coupled similarly to obtain 9 (Scheme 3). The identity and homogeneity of the product were verified by ESIMS and HPLC after each coupling and 5’-depro-
tection step. The MS data are given in Table 1. Figure 2 and Figure 3 show as an illustrative example the HPLC traces for 8a, 8b and 9 precipitated from MeOH and the filtrate of precipitation. As seen, the precipitation is virtually quantitative.

The trimer prepared was then released from the support by cleaving the disulfide linkage by TCEP reduction. The phosphate bound 2-mercaptoethyl group was removed spontaneously giving the oligonucleotide trimer expectedly as a fully

![Figure 1](image1.png)

**Figure 1:** (A) HPLC traces for the precipitated support bearing phosphate-protected 3’-T-5’ monomer having the 5’-hydroxy group detritylated (7b), and (B) HPLC traces of the filtrate after precipitation. For the chromatographic conditions, see gradient A in the Experimental section.

![Table 1](image2.png)

**Table 1:** ESIMS characterization of the support-bound nucleotides indicated in Scheme 3.

| Compound | Calculated mass | Observed mass |
|----------|-----------------|---------------|
| 7a       | 2060.0 [(M − 2H)/2]2− | 2059.9 [(M − 2H)/2]2− |
| 7b       | 1455.3 [(M − 2H)/2]2− | 1455.2 [(M − 2H)/2]2− |
| 8a       | 3067.7 [(M − 2H)/2]2− | 3067.7 [(M − 2H)/2]2− |
| 8b       | 2462.9 [(M − 2H)/2]2− | 2462.7 [(M − 2H)/2]2− |
| 9        | 2724.6 [(M − 3H)/3]3− | 2724.5 [(M − 3H)/3]3− |

![Figure 2](image3.png)

**Figure 2:** (A) HPLC traces for the precipitated support bearing phosphate-protected 3’-pTpC Bz-5’-O-DMTr (8a) and (B) HPLC traces of the filtrate after precipitation. For the chromatographic conditions, see gradient B in the Experimental section.
Figure 3: (A) HPLC traces for the precipitated support bearing phosphate-protected 3'-pTpdCBr-5'-OH dimer 8b, and (B) HPLC traces of the filtrate after precipitation of 8b. (C) HPLC traces for the precipitated support bearing phosphate-protected 3'-pTpdCBr-pdGibu-5'-O-DMTr (9). For the chromatographic conditions, see gradient A (for 8b and its filtrate) and gradient B (for 9) in the Experimental section.

Scheme 4: Cleavage of oligonucleotides from support. Reagents and conditions: (i) tris(2-carboxyethyl)phosphine hydrochloride, Et_3N, MeOH.

protected 3'-O-(2-chlorophenyl phosphate). While the phosphate and base moiety protections remained intact, the 5'-O-(4,4'-dimethoxytrityl) group was unfortunately lost (Scheme 4). It has been previously shown [26] that the disulfide linkage may be cleaved by reduction with dithiotreitol or TCEP at pH buffered to 7.6 without detritylation taking place. Elongated treatment with TCEP appeared, however, to be too harsh. Evidently, the 5'-terminal nucleoside should be inserted as a more acid tolerant 5'-O-(4-methoxytrityl) protected building block. The concentrated reaction mixture was washed with MeCN and collected washings having crude trimer were dried and purified by semi-preparative HPLC to afford pure trimer oligodeoxyribonucleotide (10).

Conclusion

Tetrakis-O-([4-{4-[(2-hydroxyethyl)disulfanylmethyl]-1H-1,2,3-triazol-1-ylmethyl]phenyl}pentaerythritol (3) has been synthesized and used as a tetrapodal soluble support for the synthesis of a fully protected trimeric oligodeoxyribonucleotide as a 3'-O-(2-chlorophenyl phosphate) by the 1-hydroxybenzotriazole promoted phosphotriester chemistry. The support enabled efficient purification of the support-bound intermediates and product by virtually quantitative precipitation from MeOH after each coupling and 5'-O-deprotection. However, on assembling the trimeric 3'-O-(2-chlorophenyl phosphate) building blocks, the 5'-terminal nucleoside should be introduced in a 5'-O-(4-methoxytrityl) protected form to prevent detritylation during the reductive cleavage of the trimer from the support.

Experimental

General: NMR spectra were recorded on a Bruker Avance spectrometer (500 or 400 MHz) at 25 °C. Chemical shifts are given in ppm and referenced relative to the residual solvent signals. RP HPLC conditions: (A) gradient elution from 25% MeCN in 0.1 mol L\(^{-1}\) Et_3NHOAc to 70% MeCN in 0.1 mol L\(^{-1}\) Et_3NHOAc in 25 min, then continued with 70% MeCN in 0.1 mol L\(^{-1}\) Et_3NHOAc to 100% MeCN in 35 min; (B) gradient elution from 25% MeCN in 0.1 mol L\(^{-1}\) Et_3NHOAc to 100% MeCN in 25 min, then continued with MeCN; An analytical
Tetrakis-O-(4-azimidomethylphenyl)pentaerythritol (1) was prepared as described previously [7].

**Tetrakis-O-[(4-acetyliothiophenyl)-1H-1,2,3-triazol-1-ylmethyl]pentaerythritol (2):** S-Propargyl thioacetate (1.73 mL, 15.0 mmol) was added to the solution of compound 1 (1.00 g, 1.51 mmol), sodium ascorbate (30 mg, 0.15 mmol) and Cu(I) (115 mg, 0.605 mmol) in dry DMAC (5.0 mL) in a Pyrex tube. The tube was degassed via three freeze–pump–thaw cycles, and the mixture was stirred at 50 °C for 12 h. Water (10 mL) was added to the reaction mixture and extracted with ethyl acetate (20 mL × 3). The combined organic layer was washed with saturated NaHCO₃ solution, dried with Na₂SO₄, and the solvents were evaporated to dryness. The residue was purified by silica gel chromatography (CH₂Cl₂/MeOH, 97:3 v/v) to give 2 (1.2 g, 75%) as a white foam.

| Mass Spectra | Peak | ppm  |
|--------------|------|------|
| ESIMS m/z    | 53+  | 53.6 |
| ESIMS m/z    | 59+  | 59.9 |

**Bis(benzotriazol-1-yl) 2-chlorophenyl phosphate:** The couplings were carried out essentially as described previously [8]. A solution of 2-chlorophenyl phosphorodichloridate (7.6 mmol, 1.88 g) in anhydrous dioxane (5.75 mL) was added in one portion to a suspension of 1-hydroxybenzotriazole (15.2 mmol, 2.06 g; dried in vacuo over P₂O₅ at 55 °C for 3 d) and pyridine (15 mmol, 1.2 mL) in anhydrous dioxane (30 mL). The reaction mixture was stirred for 2 h, and the precipitate was filtered off under anhydrous conditions to give a stock solution of bis(benzotriazol-1-yl) 2-chlorophenyl phosphate (0.2 mol L⁻¹) as a clear colorless liquid. The solution (ρ = 1.057 g L⁻¹) could be stored for several weeks at −20 °C.

**General procedure for the coupling of 1-hydroxybenzotriazole-activated phosphotriester building blocks:** The coupling cycle was analogous to that described previously [8]. 5'-O-(4,4'-Dimethoxytrityl)thymidine (0.30 g, 0.54 mmol) was dried by co-evaporation with anhydrous pyridine (3 × 5 mL) and concentrated to a small volume followed by the addition of the stock solution of bis(benzotriazol-1-yl) 2-chlorophenyl phosphate in dioxane (0.54 mmol, 0.2 mol L⁻¹, 2.72 mL), giving 5'-O-(4,4'-dimethoxytrityl)thymidine 3'-[bis(benzotriazol-1-yl) 2-chlorophenyl phosphate] 4 in dioxane. The formation of a product with zero mobility on TLC (system B) indicated that the reaction was complete. In a separate vessel, support 3 (0.20 g) was dried by co-evaporation with anhydrous pyridine (3 × 5 mL) and then 4 in dioxane and 1-methylimidazole (2 mmol, 0.218 mL) were added under nitrogen. The reaction mixture was stirred for 2 h to obtain the tetravalent nucleoside cluster 7a, transferred to a stoppered 50 mL plastic tube, and MeOH (46 mL) was added. The precipitate formed was kept at −20 °C overnight, isolated by centrifugation, and dried to give 7a (0.20 g, 70%) as a white solid. The precipitate and supernatant were analyzed by HPLC to verify the completeness of precipitation and the identity of the precipitate was verified by ESIMS (Table 1).

**General procedure for detritylation:** The detritylation cycle was analogous to that described previously [8]. Tetravalent support-bound thymidine monomer 7a (0.048 mmol, 0.20 g) was dissolved in a mixture of DCM and MeOH (1:1 v/v, 25 mL), and HCl in MeOH (0.115 mL of 1.25 mol L⁻¹ solution) was added portion wise. The reaction was monitored by TLC.
system A). Once completed, the reaction mixture was neutralized with pyridine (1 mL), and the liquid was concentrated. The resulting oil was dissolved in DCM/MeOH (1:1, 3 mL), and MeOH was added (40 mL). The precipitate formed was kept at −20 °C overnight, collected by centrifugation and dried to give the product 7b (0.120 g, 85%) as a white solid. The precipitate and supernatant were analyzed by HPLC (Figure 1) and the precipitate by ESIMS (Table 1).

**References**

1. Watts, J. K.; Corey, D. R. J. Pathol. 2012, 226, 365–379. doi:10.1002/path.2993
2. Kole, R.; Krainer, A. R.; Altman, S. Nat. Rev. Drug Discovery 2012, 11, 125–140. doi:10.1038/nrd3625
3. Usman, N.; Blatt, L. M. J. Clin. Invest. 2000, 106, 1197–1202. doi:10.1172/JCI11631
4. Li, T.; Wu, M.; Zhu, Y. Y.; Chen, J.; Chen, L. Nucleic Acid Ther. 2014, 24, 302–312. doi:10.1089/nat.2014.0490
5. Burnett, J. C.; Rossi, J. J. Chem. Biol. 2012, 19, 60–71. doi:10.1016/j.chembiol.2011.12.008
6. Krieg, A. M. Nucleic Acid Ther. 2012, 22, 77–89.
7. Kungurtsev, V.; Laakkonen, J.; Gimenez Molina, A.; Virta, P. Eur. J. Org. Chem. 2013, 6687–6693. doi:10.1002/ejoc.201300864
8. Kungurtsev, V.; Virta, P.; Lönnberg, H. Eur. J. Org. Chem. 2013, 7886–7890. doi:10.1002/ejoc.201301352
9. Gimenez Molina, A.; Jabgunde, A. M.; Virta, P.; Lönnberg, H. Beilstein J. Org. Chem. 2014, 10, 2279–2285. doi:10.3762/bjoc.10.237
10. Gimenez Molina, A.; Jabgunde, A. M.; Virta, P.; Lönnberg, H. Curr. Org. Synth. 2015, 12, 202–207. doi:10.2174/157017941166141120215703
11. de Vroom, E.; Fiddler, A.; Marugg, J. E.; van der Marel, G. A.; van Boom, J. H. Nucleic Acids Res. 1986, 14, 5885–5900. doi:10.1093/nar/14.14.5885
12. Reese, C. B.; Zhang, P.-Z. J. Chem. Soc., Perkin Trans. 1 1993, 2291–2301. doi:10.1039/p99300002291
13. Bonora, G. M.; Scremin, C. L.; Colonna, F. P.; Garbesi, A. Nucleic Acids Res. 1990, 18, 3155–3159. doi:10.1093/nar/18.11.3155
14. Colonna, F. P.; Scremin, C. L.; Bonora, G. M. Tetrahedron Lett. 1991, 32, 3251–3254. doi:10.1016/S0040-4039(00)79736-X
15. Jones, S. S.; Rayner, B.; Reese, C. B.; Ubasawa, A.; Ubasawa, M. Tetrahedron 1980, 36, 3075–3085. doi:10.1016/0040-4020(80)88035-5
16. Zuckerman, R.; Corey, D.; Schultz, P. Nucleic Acids Res. 1987, 15, 5305–5321. doi:10.1093/nar/15.13.5305
17. Gupta, K. C.; Sharma, P.; Sathyanarayana, S.; Kumar, P. Tetrahedron Lett. 1990, 31, 2471–2474. doi:10.1016/S0040-4039(00)97392-1
18. Asseline, U.; Nguyen, T. T. Tetrahedron Lett. 1990, 31, 81–84. doi:10.1016/S0040-4039(00)94339-9
19. Kumar, P.; Bose, N. K.; Gupta, K. C. Tetrahedron Lett. 1991, 32, 967–970. doi:10.1016/S0040-4039(00)92132-4
20. Bonfils, B.; Thuong, N. T. Tetrahedron Lett. 1991, 32, 3053–3056. doi:10.1016/0040-4020(91)80666-Z
21. Salo, H.; Guzaev, A.; Lönnberg, H. Bioconjugate Chem. 1998, 9, 365–371. doi:10.1021/bc970194g
22. van der Marel, G.; van Boeckel, C. A. A.; Wille, G.; van Boom, J. H. Tetrahedron Lett. 1981, 22, 3887–3890. doi:10.1016/S0040-4039(01)91336-X
23. Marugg, J. E.; McLaughlin, L. W.; Piel, N.; Tromp, M.; van der Marel, G. A.; van Boom, J. H. Tetrahedron Lett. 1983, 24, 3989–3992. doi:10.1016/S0040-4039(00)88244-1
24. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596–2599. doi:10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-D
25. Tomae, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057–3064. doi:10.1021/jo0111489
26. Semenyuk, A.; Fälde, A.; Johannson, T.; Estrem-Nilsson, C.; Blomgren, P.; Brännvall, M.; Kirsebom, L. A.; Kwałkowsk, M. J. Am. Chem. Soc. 2006, 128, 12356–12357. doi:10.1021/ja0635857
License and Terms

This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)

The definitive version of this article is the electronic one which can be found at: doi:10.3762/bjoc.11.171